

May 21, 2009

Roger Citron
Montana Department of Public Health & Human Services
Helena, MT

Dear Mr. Citron:

Your UCB, Inc. Representative Bobby White contacted the Medical Affairs Department with your request for information regarding Cimzia® (certolizumab pegol). Thank you for letting us know how we can assist you. Specifically, you requested information regarding a Cimzia® medical summary for Rheumatoid Arthritis.

Cimzia® is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Cimzia® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).

Please review the enclosed Cimzia® package insert for complete prescribing information.

This material is provided in response to your specific request and may contain information that is not part of the FDA-approved product labeling. If you have additional questions or a patient who has experienced adverse events related to the abovementioned product(s), please contact us toll free at (866) 822-0068 (press option 4 to report an adverse event or option 9 for Medical Information). We appreciate your interest in UCB, Inc., and in our products.

Sincerely,

A handwritten signature in black ink, appearing to read "Erica Werts", with a stylized flourish at the end.

Erica Werts, PharmD
Senior Medical Information Specialist

US-EWE/EW/5810

Enclosure(s):
Cimzia® Package Insert
Cimzia® RA - Medical Summary